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Treatment responseThe present case–control study involving 750 cases and equal number of healthy controls investigates the asso-
ciation of polymorphism in cytochrome P450 2C9 (CYP2C9) with head and neck squamous cell carcinoma
(HNSCC) and response in patients receiving chemotherapy or combination of radio-chemotherapy. The frequen-
cy of heterozygous or homozygous genotypes ofCYP2C9*2& CYP2C9*3, which leads to the poormetabolizer (PM)
genotype was signiﬁcantly higher in HNSCC cases when compared to the healthy controls resulting in signiﬁ-
cantly increased risk in the cases. Tobacco use in the form of tobacco smoking or tobacco chewing was found
to increase the risk several fold in cases when compared to the non-tobacco users. Likewise, alcohol intake in
cases with variant genotypes of CYP2C9*2 or CYP2C9*3 also signiﬁcantly increased the HNSCC risk in cases
when compared to non-alcohol users. Further, majority of the cases carrying variant alleles of both CYP2C9*2
or CYP2C9*3 were found to respond poorly to the chemotherapy or combination of radio-chemotherapy. The
data suggests a signiﬁcant association of the CYP2C9 polymorphism with HNSCC and treatment outcome.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Head and neck squamous cell carcinoma (HNSCC) accounts for
approximately 5% of all cancers worldwide. In India they account for
one-quarter to one-third of male cancers and one-tenth of cancers in
females. HNSCC is often associated with heavy tobacco and alcohol
use. People who use both tobacco and alcohol are at greater risk for de-
veloping these cancers than people who use either tobacco or alcohol
alone (Hunter et al., 2005; Brennan and Boffetta, 2004). Polymorphisms
in genes such as cytochrome P450s (CYPs) & glutathione-S-transferases
(GSTs), involved in the metabolism and detoxiﬁcation of alcohol and
constituents of tobacco are shown to inﬂuence an individual's suscepti-
bility to cancer (Bartsch et al., 2000; Gronau et al., 2003). Studies includ-
ing meta- and pooled analysis have shown that polymorphisms inerms of the Creative Commons
which permits non-commercial
d the original author and source
ivision, CSIR-Indian Institute of
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.
armar).
ity University, Sector 125, Noida
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lished by Elsevier B.V. All rights reserphase I (CYP1A1, CYP2E1) & phase II (GST) enzymes are associated
with tobacco induced HNSCC (Hashibe et al., 2003; Singh et al., 2008;
Shah et al., 2008).
CYP2C9 is one of the major drugs metabolizing CYP in human liver
and contributes to the metabolism of a number of clinically important
drugs such as anticoagulants and antihypertensives (Hermida et al.,
2002). CYP2C9 is also known to be involved in the metabolism of
some of the anti-neoplastic drugs such as cyclophosphamide, etoposide,
tamoxifen and ifosfamide (Schaik, 2005; Bosch et al., 2006). A 3-fold
lower intrinsic clearance for cyclophosphamide was observed with
recombinant CYP2C9*2 and CYP2C9*3 protein when compared to
CYP2C9*1 protein in a yeast expression system (Griskevicius et al.,
2003). The MDRmodulator, verapamil, has been reported to be metab-
olized by CYP2C9, whichmay have an impact on the concomitant use of
chemotherapeutic drugs and verapamil (Busse et al., 1995). CYP2C9
enzyme has been shown to play a key role in the metabolism of non-
steroidal anti-inﬂammatory drugs (NSAIDs) that are frequently used
in cancer patients suggesting that the doses of NSAIDs, should be care-
fully individualized in these patients (Goldstein and De Morais, 1994).
In addition, CYP2C9 enzyme also metabolizes several carcinogenic
and mutagenic substrates including heterocyclic aromatic amines and
polycyclic aromatic hydrocarbons, PAHs (Shou et al., 1996; Nakamura
et al., 1999). It has also been shown that some of the reactions catalyzed
by CYP2C9 lead to detoxiﬁcation of carcinogens (Bauer et al., 1995; Chan
et al., 2004). Genetic polymorphism has also been reported for CYP2C9.
CYP2C9*2 and CYP2C9*3 genotypes account for “poormetabolizer” (PM)ved.
9S.S. Yadav et al. / Applied & Translational Genomics 3 (2014) 8–13phenotype resulting in the slow metabolism of drugs and other sub-
strates metabolized by CYP2C9 (Miners and Birkett, 1998; Higashi
et al., 2002). Signiﬁcant differences are known to exist in the distribu-
tion of the variant alleles of CYP2C9 in different population. In general,
the polymorphism in CYP2C9 ismore frequent in Caucasianswhen com-
pared to Orientals (Chinese & Japanese population) (Wang et al., 1995;
Takahashi et al., 2003; Musbah et al., 2007). An increased frequency of
CYP2C9*2 allele in the patients with lung cancer has been reported
(London et al., 1996). Variant alleles of CYP2C9 were reported to
increase the risk of distal colorectal adenoma (Chan et al., 2004;
Tranah et al., 2005).
Previous study from our laboratory has shown that PMs of CYP2C19
are involved inmodulating the susceptibility to HNSCC and exhibit poor
response to chemotherapy (Yadav et al., 2008). The present study,
therefore, now attempted to investigate the association of CYP2C9 geno-
types which leads to poormetabolizer (PM) statuswith HNSCC risk and
outcome of treatment in the patients receiving chemotherapy and
combination of radio-chemotherapy. Attempts were also made to
investigate the interaction of CYP2C9*2 & CYP2C19*3 genotypes with
tobacco and alcohol in modifying the HNSCC risk.
2. Materials and methods
2.1. Study subjects
A case–control study was conducted at King George's Medical Uni-
versity (KGMU), Lucknow, India. 750 males suffering from HNSCC and
visiting the OPD facility of Radiotherapy Department of KGMU and
equal number of controls were included in the study. The cases had
squamous cell carcinoma of the oral cavity or pharynx or larynx which
was conﬁrmed by cytological, imaging and histopathological examina-
tions and were advised a combination treatment of chemo- and radio-
therapy. All the subjects included in the study belonged to the same
ethnic group (Indo-European community) of North India. Controls
were frequency-matched to cases by year of birth in 5-year classes.
Based on medical check-up, controls were not found to suffer from
any chronic disease.
The protocol of the study was approved by the human ethics com-
mittee of Chhatrapati Shahuji Maharaj Medical University, Lucknow,
where the patients were registered and it conforms to the provisions
of the declaration of Helsinki. Informed consent was obtained from
the study subjects for inclusion in the study and before the collection
of blood samples and it was also ensured that the subject anonymity
was maintained. All study subjects completed a questionnaire covering
medical, residential and occupational history. Information pertaining to
dietary habits, family history of disease, smoking, tobacco chewing and
alcohol drinking was also included in the questionnaire ﬁlled by the
subjects. Subjects having regular smoking habits and smoking index
(cigarettes/day × 365 days) of 730 or more were classiﬁed as smokers
(Quinones et al., 2001). Likewise, smokeless tobacco dose was estimat-
ed as ‘chewing year’ (i.e. CY = frequency of tobacco chewed or kept/
day × duration of year). Thosewho had CY of 365 ormorewere consid-
ered as tobacco chewers (Sikdar et al., 2003). Similarly, cumulative ex-
posure to alcohol drinking was derived by multiplying the total yearly
consumption of alcohol (in L/year) by the duration of habitual alcohol
drinking (in years). Those who had cumulative exposure to alcohol
about 90 L were considered as regular alcohol users in our study
(Hung et al., 1997).
2.2. DNA isolation and CYP2C9 genotyping
500 μL blood samples collected in citrate containing tubes from the
study subjects were processed for the isolation of genomic DNA whole
blood using QIAamp DNAmini kit (Qiagen, CA) following the manufac-
turers' protocol. For identifying the polymorphism in CYP2C9 (CYP2C9*2
and CYP2C9*3), the reaction mixture in 50 μL contained 1× buffer(10 mM Tris–Hcl pH 8.3, 1.5–3.0 mM of MgCl2, 25 mM KCl), 200 mM
of each nucleotide, 200 nM of each of CYP2C9*2 or 2C9*3 primers
(Wang et al., 1995), 1.5 unit of Taq polymerase (MBI Fermentas,
Germany), 100 ng of genomic DNA and sterile milliQ water and was
processed for PCR. Ampliﬁed PCR products were digested with AvaII
or NsiI (MBI Fermentas, Germany) for identifying CYP2C9*2 and
CYP2C9*3 respectively (Wang et al., 1995). The products were resolved
by 3% agarose gel containing ethidium bromide as described earlier
(Wang et al., 1995).
For quality control, randomly 10% of the samples were selected and
re-genotyped to conﬁrm the authenticity of the results obtained earlier
and they were found to be in 100% concordance.
2.3. Statistical analysis
We determined whether genotype or allele frequencies of CYP2C9
polymorphism amongst the cases and controls were in Hardy–
Weinberg equilibrium (HWE) using the standard chi square tests. The
association between genetic polymorphisms and risk of HNSCCwas es-
timated by calculating crude odds ratio (OR). A p-value of b0.05 was
considered statistically signiﬁcant. The statistical analysis was per-
formed with the SPSS software package (version 11.0 for Windows;
SPSS Chicago, IL). The power of the present study was found to be
N80% as analyzed by power genetic association analysis software
(http://dceg.cancer.gov/bb/tools/pga) at the level of signiﬁcance α =
0.05 with sample size of 750 in HNSCC and 750 in controls.
2.4. Treatment and treatment response
Patients were subjected to 3 cycles of neo-adjuvant chemotherapy
(NACT), before radiotherapy or concurrent chemotherapy with radio-
therapy (CT–RT). Each cycle of NACT consisted of cisplatin (50 mg/day)
from days 1 to 3 and 5-ﬂuorouracil (1 g/day) from days 1 to 3. Each
cycle was administered once in 3 weeks. CT–RT included administration
of 50 mg of cisplatin once every week for 7 weeks along with 70 Gy of
radiation (which could be 200 cGy or 2 Gy/fraction depending on
tumor size), daily for 7 weeks.
For assessing the treatment response, patients are asked to return for
follow-up for ﬁve years. During follow-up, monitoring of the patients is
done by thorough serial inspection of the head and neck region —
looking for disease recurrence as well as second primary tumors. On
the basis of WHO criteria the treatment outcome is divided into the
following three categories:
i. Complete response (CR): No detectable tumor
ii. Partial response (PR): More than or equal to 75% decrease in tumor
in its largest dimension
iii. No response (NR): Less than or equal to 50% decrease in tumor in its
largest dimension
Those exhibiting CR & PR are categorized as responders while pa-
tients exhibiting NR are classiﬁed as non-responders (Yadav et al.,
2008).
3. Results
The distribution of demographic variables and putative risk factors
of HNSCC are summarized in Table 1. In general, cigarette smoking,
tobacco chewing and daily alcohol use were found to be prevalent in
the patients when compared to the controls (Table 1). Table 2 summa-
rizes the genotypic frequencies of CYP2C9*2 & CYP2C9*3 in the controls
and cases respectively. The distribution of CYP2C9*2 (chi square:
34.93 at 1 d.f.) and CYP2C9*3 (chi square: 32.49 at 1 d.f.) genotypes in
the controls showed deviation from Hardy–Weinberg equilibrium
(HWE) while that of CYP2C19*2 (chi square: 3.22 at 1 d.f.) was in
HWE, though at a borderline signiﬁcance. The frequency of heterozy-
gous genotypes (CT) of CYP2C9*2 polymorphismwas found to be higher
Table 1
Distribution of demographic variables and putative risk factors of HNSCC cases.
Characteristics Controls n (%) Cases n (%)
Subjects 750 750
Age (mean ± S.D.) 50 ± 11 57 ± 9.2
Non-tobacco chewers 545 (72.6) 475 (63.3)
Smokers 164 (30) 394 (83.0)
Alcohol users 55 (10.0) 109 (23.0)
Tobacco chewers 205 (27.4) 275 (36.7)
Non-smokers 547 (72.9) 326 (43.4)
Tobacco chewers 170 (31) 251 (77.0)
Alcohol users 71 (13.0) 75 (23.0)
Smokers 203 (27.1) 424 (56.6)
Non-alcohol users 643 (85.7) 550 (73.3)
Tobacco chewers 129 (20.0) 259 (47.0)
Smokers 116 (18.0) 281 (51.0)
Alcohol users 107 (14.3) 200 (26.7)
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in frequency resulted in an increased OR (2.22; 95% CI 1.51–3.26) in
cases which was found to be statistically signiﬁcant. Likewise, the
frequency of homozygous genotype (TT) was slightly higher in cases
(7.7%) when compared to the controls (4.6%) that resulted in an
increase in risk (OR: 1.75) which, however, was not found to be statis-
tically signiﬁcant. Adjustment of the data for age, cigarette smoking,
and tobacco chewing and alcohol consumption revealed that the
risk continued to be signiﬁcantly increased (Adj. OR: 2.72; 95% CI:
1.78–4.14) in the cases with heterozygous genotype (CT) of CYP2C9*2
polymorphism (Table 2). Likewise, the frequency of heterozygous and
homozygous mutant genotypes CYP2C9*3 was found to be increased
in the cases when compared to the controls that increased the HNSCC
risk which was statistically signiﬁcant. Adjustment of the data for age,
cigarette smoking, tobacco chewing and alcohol consumption revealed
that the risk continued to be signiﬁcantly increased in the cases with
heterozygous genotype (AC) of CYP2C9*3 polymorphism (Table 2).
As with CYP2C9*2 polymorphism, an increase in the frequency of
heterozygous genotype (45.4%) of CYP2C19*2 was observed in cases
when compared to the controls (34.3%). The increase in frequency
was associated with an increase in the OR (1.60; 95% CI 1.17–2.16)
which was found to be statistically signiﬁcant. An increase in the
frequency of homozygous mutant genotype (18%) was also observed
in the cases when compared to the controls (8.3%) and that resulted
in a statistically signiﬁcant increase in OR (2.43; 95% CI 1.17–2.16) in
the cases (Table 2). Adjustment of the data for age, cigarette smoking,
tobacco chewing and alcohol consumption revealed that the risk contin-
ued to be signiﬁcantly increased in the cases for both, heterozygous
(adjusted OR: 2.05; 95% CI: 1.45–2.91; p-value: 0.000) or homozygous
mutant genotype (adjusted OR: 3.25; 95% CI: 1.93–5.49; p-value:
0.000) when compared to the controls (Table 2).
The effect of interaction of the risk modiﬁers such as tobacco
chewing, cigarette smoking and alcohol consumption with the CYP2C9Table 2
Distribution of CYP2C9*2 & CYP2C9*3 genotypes amongst HNSCC cases and healthy controls.
Genotype frequency Control
n = 750 (%)
Patients
n = 750 (%)
Cru
(9
CYP2C9*2
CC 611 (81.4) 493 (65.7) 1 (
CT 105 (14) 200 (26.6) 2.3
TT 34 (4.6) 57 (7.7) 2.1
CYP2C9*3
AA 638 (85) 540 (72) 1 (
AC 90 (12) 173 (23) 2.2
CC 22 (3) 37 (5) 1.9
OR: Odds ratio; CI: conﬁdence interval; ref.: reference category, Adjusted ORa: adjusted in mu
alcohol, tobacco chewing. Values in bold are statistically signiﬁcant at the 0.05 levels.genotypes in the controls and cases is summarized in Table 3. The num-
ber of individuals with variant genotypes (homozygous & heterozygous)
of CYP2C9*2was signiﬁcantly increased in cases (38.5%), who were reg-
ular tobacco chewers as compared to the controls (12.5%) with similar
habit of tobacco chewing. The increase in the frequency resulted in
several fold statistically signiﬁcant increase in the OR (4.3; 95% CI:
2.2–8.6) amongst the tobacco chewing cases. As observed with
CYP2C9*2, the frequency of individuals who were regular tobacco
chewers with variant genotypes of CYP2C9*3 was also increased signiﬁ-
cantly in cases (35.6%) when compared to the controls (14.6%). The in-
crease in the frequency resulted in 3–4 fold statistically signiﬁcant
increase in the risk (OR: 3.2, 95% CI: 1.7–6.1) (Table 3).
Cigarette smoking also increased the risk to HNSCC in the cases with
CYP2C9 polymorphism when compared to the smokers in the controls
(Table 3). The frequency of individuals who were regular smokers and
carried variant genotypes of CYP2C9*2 (40.9%) was signiﬁcantly
increased in the cases as compared to the controls (13.7%). The OR asso-
ciatedwith cigarette smoking increased several fold in the patients with
the variant genotypes of CYP2C9*2 (4.4; 95% CI: 2.3–8.4) which was
found to be statistically signiﬁcant (p-value: 0.000). As observed with
CYP2C9*2 variants, the number of cases with variant genotypes of
CYP2C9*3 was also increased amongst smokers (30.3%) as compared
to the controls (14.7%). Further, this increase was associated with an in-
creased risk (OR: 2.5, 95% CI: 1.3–4.8), whichwas found to be statistical-
ly signiﬁcant (Table 3).
Our data further showed that frequency of the individuals with var-
iant genotypes of CYP2C9*2 and whowere regular alcohol users signiﬁ-
cantly increased in the cases (57%) when compared to the controls
(16.9%). This increase in frequency was associated with almost 4-fold
increase in the risk (OR: 3.7, 95% CI: 2.0–7.0) to HNSCC in the cases
(Table 3). As observed with CYP2C9*2 variants, the number of cases
with variant (homozygous & heterozygous) genotypes of CYP2C9*3
also increased amongst alcohol users (28.2%) as compared to the con-
trols (8.4%). A similar increase in risk was also observed in cases
amongst the alcohol users with variant genotypes of CYP2C9*3 when
compared to the alcohol users in the controls. Moreover, this increase
in the risk (OR: 4.3; 95% CI: 1.9–9.8) was also found to be statistically
signiﬁcant (Table 3).
A follow-up studywas also carried out in 390 patients to investigate
the effect of treatment on the patients with different genotypes of
CYP2C9 (Table 4). Amongst the patients with wild type genotype of
CYP2C9 (CYP2C9*1), 73% responded to the treatment of chemo- and ra-
diotherapy (Responders) while 27% showed almost negligible response
(non-responders). Amongst the patients with variant genotypes of
CYP2C9*2, only 37% could be categorized as responders while 63%
were found to be non-responders. Likewise, amongst the PMs with
CYP2C9*3 genotypes, only 34.2% responded to the treatment while
65.8% could be categorized as non-responders (Table 4). Interestingly,
amongst 7 cases who carried compound heterozygous genotype of
CYP2C9*2/*3 (cases with both the heterozygous i.e. CYP2C9*1/*2 &de OR
5% CI)
p-Value Adjusted ORa
(95% CI)
p-value
ref.) 1 (ref.)
6 (2.8–3.1) 0.00 2.5 (1.88–3.32) 0.00
(1.33–3.22) 0.00 2.3 (1.4–3.75) 0.00
ref.) 1 (ref.)
7 (1.72–3.0) 0.00 2.6 (1.92–3.52) 0.00
8 (1.15–3.4) 0.01 2.3 (1.3–4.1) 0.00
ltivariate logistic regression models including age, smoking status, daily consumption of
Table 3
Interaction between CYP2C9 genotypes and tobacco chewing, smoking and alcohol consumption and risk to HNSCC.
Tobacco chewers Non-tobacco chewers
Genotypes Controls
n = 205 (%)
Cases
n = 275 (%)
OR
(95% CI)
p-Value Controls
n = 545 (%)
Cases
n = 475 (%)
OR
(95% CI) p-value
p-Value
CYP2C9*2
Wild type 180 (87.9) 169 (61.5) 1 (ref.) 431 (79.1) 324 (68.2) 1 (ref.)
Variant 25 (12.1) 106 (38.5) 4.5 (2.78–7.32) 0.00 114 (20.9) 151 (30.8) 1.76 (1.3–2.3) 0.00
CYP2C9*3
Wild type 179 (87.2) 177 (64.4) 1 (ref.) 459 (84.3) 363 (80.1) 1 (ref.)
Variant 26 (12.8) 98 (35.6) 3.8 (2.35–6.2) 0.00 86 (15.7) 112 (23.5) 1.65 (1.2–2.25) 0.00
Smokers Non-smokers
Genotypes Controls
n = 203 (%)
Cases
n = 424 (%)
OR
(95%CI)
p-Value Controls
n = 547 (%)
Cases
n = 326 (%)
OR
(95% CI)
p-Value
CYP2C9*2
Wild type 176 (86.5) 261 (61.5) 1 (ref.) 435 (79.6) 232 (71.3) 1 (ref.)
Variant 27 (13.5) 163 (38.5) 4.0 (2.6–6.4) 0.00 112 (20.4) 94 (28.7) 1.6 (1.14–2.2) 0.00
CYP2C9*3
Wild type 175 (86) 293 (69) 1 (ref.) 463 (84.7) 247 (75.7) 1 (ref.)
Variant 28 (14) 131 (31) 2.8 (1.78–4.4) 0.00 84 (15.3) 79 (24.3) 1.8 (1.2–2.5) 0.00
Alcohol users Non-alcohol
Genotypes Controls
n = 107 (%)
Cases
n = 200 (%)
OR
(95% CI)
p-Value Controls
n = 267 (%)
Cases
n = 148 (%)
OR
(95% CI)
p-Value
CYP2C9*2
Wild type 91 (85) 114 (57.0) 1 (ref.) 520 (80.9) 379 (68.9) 1 (ref.)
Variant 16 (15) 86 (43.0) 4.3 (2.35–7.8) 0.00 123 (19.1) 171 (31.1) 1.9 (1.46–2.2) 0.00
CYP2C9*3
Wild type 95 (88.9) 144 (71.8) 1 (ref.) 543 (84.5) 396 (72) 1 (ref.)
Variant 12 (11.1) 56 (28.2) 3.1 (1.5–6.04) 0.00 100 (15.5) 154 (28) 2.1 (1.6–2.8) 0.00
OR: odds ratio; CI: conﬁdence interval; ref.: reference category; variant — heterozygous and homozygous mutant genotype. Values in bold are statistically signiﬁcant at the 0.05 levels.
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while only 2 (28.6%) were found to be responders (Table 4).
4. Discussion
The data of the present study has shown that functionally important
polymorphism of CYP2C9 exists in North Indian population. The fre-
quency of the variant genotypes of CYP2C9 (CYP2C9*1/*2 & CYP2C9*3)
was found to be higher (14% & 3% respectively) than that reported in
South Indian (7% and 1%) population (Adithan et al., 2003; Rosemary
et al., 2005). This could be partly attributed to the population structure
of India comprising a mixture of endogamous ethnic groups (Rosemary
et al., 2005). The frequency of the CYP2C9*2 genotypes in our control
population was higher than that observed in other Asian populationTable 4
Treatment responses in patients of HNSCC with CYP2C9 genotypes.
Genotypes Cases
n = 390 (%)
Responders
(%)
Non-responders
(%)
p-Value
CYP2C9*1 148 (37.8) 108 (73.0) 40 (27.0) Ref
CYP2C9*2 142 (36.5) 54 (38.0) 88 (62.0) 0.0000*
CYP2C9*3 0.0000* 36 (35.6) 64 (64.4) 0.0000*
VarCYP2C9*2/*3 96 (24.7) 36 (37.7) 60 (62.3) 0.0000*
HomCYP2C9*2/*3 12 (3.0) 3 (25.0) 9 (75.0) 0.0000*
Responder: Based on 50% reduction in tumor size, clinical response 50% & above by
imaging, CTMRI, endoscopy techniques & symptomology (based on WHO criteria).
Non-responder: Less than 50% clinical response.
Var: Cases carrying both homozygous and heterozygous variants of both CYP2C9*2 &
CYP2C9*3. *p b 0.05 is considered statistically signiﬁcant.
Hom: Cases carrying only homozygous variants of both CYP2C9*2 & CYP2C9*3.(Chinese & Japanese) but was comparable to the Caucasians (Wang
et al., 1995; Takahashi et al., 2003; Musbah et al., 2007). It was observed
that the CYP2C9*3 polymorphism was more common in North Indian
population. The frequency of the variant genotype CYP2C9*3 was rela-
tively higher (3%) when compared to the Chinese population (0.01%)
but relatively lesser than found in the Caucasians (7%) (Wang et al.,
1995; Takahashi et al., 2003; Musbah et al., 2007). As observed with
other studies (Higashi et al., 2002; Kramer et al., 2008;), the distribution
of CYP2C9*2 and CYP2C9*3 genotypes in the controls showed deviation
from Hardy–Weinberg equilibrium (HWE) which may be possibly due
to recent population admixture. As reported earlier (Kudzi et al.,
2009), CYP2C9*2 and CYP2C9*3 genotypes do not exhibit linkage
disequilibrium (LD) in our study.
A relatively higher prevalence of cases with variant genotypes of
CYP2C9*2 or *3 have clearly indicated that individuals inheriting PM
genotypes of CYP2C9 are at increased risk to develop HNSCC. Though
the association of CYP2C9 polymorphism has not been relatively well
characterized with HNSCC, an increased frequency of CYP2C9*2 allele
has been reported in the cases suffering from lung cancer (Ozawa
et al, 1999; London et al., 1996). Using reconstituted system, micro-
somes prepared from Saccharomyces cerevisiae expressing recombinant
human CYPs, CYP2C9 was found to catalyze both activation and inacti-
vation reactions of benzo[a]pyrene, B[a]P (Bauer et al., 1995; Shou
et al., 1994; Gautier et al., 1996). Similarly, amongst human CYPs
expressed in vaccinia virus, CYP2C9 gave the highest activity for theme-
tabolism of BP-7,8 diol to the diol epoxides, thus identifying the role of
CYP2C9 in the metabolism and activation of B[a]P (Bauer et al., 1995;
Shou et al., 1994; Gautier et al., 1996). Further, higher afﬁnity for
CYP2C9 has been shown for B[a]P when compared to PAH-
metabolizing CYPs such as CYP1A and 2E1 and B[a]P is reported to be
mutagenically activated by CYP2C9 and 2C19 along with other CYPs
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CYP2C9 is involved in the detoxiﬁcation of PAHs derived from tobacco
smoke (Sugimoto et al., 2004; Bauer et al., 1995; Tranah et al., 2005;
Chan et al., 2004). Consistent with these reports, a high correlation
has also been observed between total DNA adducts and CYP2C isoen-
zymes in larynx (Degawa et al., 1994). Thus, the association of CYP2C9
polymorphism with HNSCC risk could be attributed to the possible in-
volvement of CYP2C isoenzymes in the metabolic activation as well as
detoxiﬁcation of PAHs and other tobacco derived products (Degawa
et al., 1994).
Our study has further indicated that the risk toHNSCCwas increased
in cases who were tobacco or alcohol users, suggesting that interaction
of CYP2C9 genotypeswith tobacco or alcohol increases the susceptibility
to HNSCC. The increased risk observed in cases using tobacco with PM
genotypes of CYP2C9 could thus be explained by higher afﬁnity of
CYP2C9 for B[a]P (Yilmaz et al., 2001). CYP2C9 variant alleles have also
been associated with altered metabolism of alkylating agents that are
well established mutagens (Chang et al., 1997). It has also been shown
that the risk of colorectal cancer or gastric cancer was found to be in-
creased in cases who had a history of smoking and carried PM geno-
types of CYP2C9 (Sugimoto et al., 2005; Tranah et al., 2005). An
association has also been reported between high levels of bronchial
bulky DNA adduct with CYP2C9 genotypes in lung cancer cases with in-
creased formation of bronchial bulky DNA adduct in cases with
CYP2C9*2 alleles compared to those with CYP2C9*3 (Ozawa et al,
1999). Likewise, an increase in risk in cases of drinking alcohol with
CYP2C9 PM genotypes has suggested that alcohol possibly interacts
with CYP2C9 genotypes in increasing the risk to HNSCC. Epidemiological
studies have also reported that alcohol acts synergistically with tobacco
to promote carcinogenesis in HNSCC. Though notmuch data is available
on interaction of CYP2C9 genotypes & alcohol, ethanol is known to in-
hibit CYP2C9 activity (Hamitouche et al., 2006). The increase in risk in al-
cohol users could be explained by delayed detoxiﬁcation of tobacco
derived products in cases with PM genotypes of CYP2C9.
Our study has further shown that chemotherapeutic response is
modiﬁed in patients with PM genotypes of CYP2C9. The poor response
rate in the patients with PMgenotypes and treatedwith radio & chemo-
therapy regimen could probably be a result of decreased availability of
metabolites in PMs. Pharmacogenetic studies have shown that
polymorphism in genes involved in drug metabolism and transport
inﬂuences interindividual variability in drug efﬁcacy and adverse effects
in cancer treatment (Schaik., 2005; Bosch et al., 2006; Dai et al.,
2008). Cases carrying variant alleles of thiopurine methyltransferase
(TPMT) or dihydropyrimidine dehydrogenase (DPYD) or UDP-
glucuronosyltransferase 1A1 (UGT1A1) were found to be predisposed
to the toxicity/adverse effects associated with the drugs metabolized
by these enzymes (Weinshilboum, 2001; Van et al., 2002). It has been
reported that the dose and therapeutic response for several drugs
in the cases vary according to the genotypic status of CYP2C9
(Kirchheiner et al., 2004; Sanderson et al., 2005). CYP2C subfamily
(including CYP2C9 and CYP2C19) is involved in themetabolism of com-
monly used anticancer drugs such as ifosfamide, cyclophosphamide,
thalidomide and could have an impact on the efﬁcacy & toxicity of che-
motherapeutic agents & other drugs used in standard oncology (Chang
et al., 1997; Ando et al., 2002). In vitro studies have demonstrated that
wild type CYP2C9 was more efﬁcient than the mutant allele CYP2C9*3
in cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation
(Chang et al., 1997). Kinetic studies have revealed a 3-fold lower intrin-
sic clearance (Vmax/Km) for cyclophosphamide in a yeast expression
system with recombinant CYP2C9*2 and CYP2C9*3 protein when com-
pared to CYP2C9*1 protein (Griskevicius et al., 2003). A recent study
from our laboratory has also shown the involvement of PMs of
CYP2C19 in modulating the chemotherapeutic outcome in HNSCC
cases (Yadav et al., 2008).
In conclusion, the results of the present study have demonstrated
that CYP2C9 variants modulate the susceptibility to HNSCC. A severalfold increase in the risk to HNSCC in the cases with variant genotypes
(PMs) of CYP2C9 and who were tobacco or alcohol users have indicated
that CYP2C9 genotypes interact with environmental risk factors in
modifying the susceptibility to HNSCC. Furthermore, it was also demon-
strated that PMs ofCYP2C9modify the treatment outcome in cases receiv-
ing chemotherapy or a combination of radio- and chemotherapy.
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